臨床眼科63巻2号

2009年02月発行

特集 未熟児網膜症診療の最前線

未熟児網膜症と血管内皮増殖因子

著者： 加地秀¹

所属機関： ¹名古屋大学大学院医学系研究科頭頸部・感覚器外科学講座（眼科学）

ページ範囲：P.165 - P.172

文献概要

はじめに

　血管内皮増殖因子（vascular endothelial growth factor：VEGF）は血管新生のメカニズムにおいて中心的な役割を担うタンパクである。未熟児網膜症（retinopathy of prematurity：ROP）においては虚血網膜でVEGFの発現が増大，その結果として新生血管が発生し，硝子体出血，増殖膜，そして網膜剝離などを生じる。そのため，VEGFを標的とした治療法は，この疾患を治療するうえで非常に重要な手法の1つとなりうる。

　本稿では，虚血によるVEGF発現と新生血管発生のメカニズムを述べるとともに，未熟児網膜症眼内におけるVEGFとそれを標的とした治療の可能性について述べる。

参考文献

1）Leung DW, Cachianes G, Kuang WJ et al：Vascular endothelial growth factor is a secreted angiogenic mitogen. Science　246：1306-1309, 1989

2）Senger DR, Galli SJ, Dvorak AM et al：Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science　219：983-985, 1983

3）Bossi E, Koerner F：Retinopathy of prematurity. Intensive Care Med　21：241-246, 1995

4）Pierce EA, Avery RL, Foley ED et al：Vascular endothelial growth factor/vascular permeability factor expression in a mouse model of retinal neovascularization. Proc Natl Acad Sci USA　92：905-909, 1995

regulated gene expression. FASEB J　16：1151-1162, 2002

levels. J Cell Sci　116：3041-3049, 2003

7）Ferrara N, Davis-Smyth T：The biology of vascular endothelial growth factor. Endocr Rev　18：4-25, 1997

8）Hanahan D：Signaling vascular morphogenesis and maintenance. Science　277：48-50, 1997

9）Aiello LP, Avery RL, Arrigg PG et al：Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med　331：1480-1487, 1994

10）Lashkari K, Hirose T, Yazdany J et al：Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity. Am J Pathol　156：1337-1344, 2000

11）Umeda N, Ozaki H, Hayashi H et al：Colocalization of Tie2, angiopoietin 2 and vascular endothelial growth factor in fibrovascular membrane from patients with retinopathy of prematurity. Ophthalmic Res　35：217-223, 2003

12）Sönmez K, Drenser KA, Capone A Jr et al：Vitreous levels of stromal cell-derived factor 1 and vascular endothelial growth factor in patients with retinopathy of prematurity. Ophthalmology　115：1065-1070, 2008

13）Ito N, Kachi S, Kondo M et al：Concentration of Vascular Endothelial Growth Factor in aqueous humor of eyes with advanced retinopathy of prematurity. ARVO抄録．演題番号1406，2008

14）Aiello LP, Pierce EA, Foley ED et al：Suppression of retinal neovascularization in vivo by inhibition of vascular endothelial growth factor（VEGF）using soluble VEGF-receptor chimeric proteins. Proc Natl Acad Sci USA　92：10457-10461, 1995

15）Ferrara N, Hillan KJ, Gerber HP et al：Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov　3：391-400, 2004

16）Avery RL, Pieramici DJ, Rabena MD et al：Intravitreal bevacizumab（Avastin）for neovascular age-related macular degeneration. Ophthalmology　113：363-372.e5, 2006

17）Iturralde D, Spaide RF, Meyerle CB et al：Intravitreal bevacizumab（Avastin）treatment of macular edema in central retinal vein occlusion：a short-term study. Retina　26：279-284, 2006

18）Arevalo JF, Fromow-Guerra J, Quiroz-Mercado H et al：Primary intravitreal bevacizumab（Avastin）for diabetic macular edema：results from the Pan-American Collaborative Retina Study Group at 6-month follow-up. Ophthalmology　114：743-750, 2007

19）Rizzo S, Genovesi-Ebert F, Di Bartolo E et al：Injection of intravitreal bevacizumab（Avastin）as a preoperative adjunct before vitrectomy surgery in the treatment of severe proliferative diabetic retinopathy（PDR）. Graefes Arch Clin Exp Ophthalmol　246：837-842, 2008

20）Sawada O, Kawamura H, Kakinoki M et al：Vascular endothelial growth factor in aqueous humor before and after intravitreal injection of bevacizumab in eyes with diabetic retinopathy. Arch Ophthalmol　125：1363-1366, 2007

21）Kusaka S, Shima C, Shimojyo H et al：Efficacy of intravitreal injection of bevacizumab for severe retinopathy of prematurity：a pilot study. Br J Ophthalmol　92：1450-1455, 2008

22）Avery RL, Pearlman J, Pieramici DJ et al：Intravitreal bevacizumab（Avastin）in the treatment of proliferative diabetic retinopathy. Ophthalmology　113：1695.e1-1695.15, 2006

23）Arevalo JF, Maia M, Flynn HW Jr et al：Tractional retinal detachment following intravitreal bevacizumab（Avastin）in patients with severe proliferative diabetic retinopathy. Br J Ophthalmol　92：213-216, 2008

24）伊藤典枝・寺崎浩子：未熟児網膜症の手術治療―新しい流れ．臨眼　62（増）：304-307，2008

25）Gragoudas ES, Adamis AP, Cunningham ET Jr et al：Pegaptanib for neovascular age-related macular degeneration. N Engl J Med　351：2805-2816, 2004

26）Brown DM, Kaiser PK, Michels M et al：Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med　355：1432-1444, 2006

27）Rosenfeld PJ, Brown DM, Heier JS et al：Ranibizumab for neovascular age-related macular degeneration. N Engl J Med　355：1419-1431, 2006

28）Ishida S, Usui T, Yamashiro K et al：VEGF164-mediated inflammation is required for pathological, but not physiological, ischemia-induced retinal neovascularization. J Exp Med　198：483-489, 2003